, and smaller AHI reduction (-31.8 vs -53.1, p < 0.001) than those in the group in whom treatment succeeded. There were no significant differences in polysomnographic, cephalometric, or visual 
Introduction
Obstructive sleep apnea (OSA) is a prevalent disorder that is characterized by pauses in breathing caused by obstruction of the upper airway during sleep. Recent estimates suggest that as many as 7% of men and 5% of women in the United States are affected by OSA. 1 The prevalence of OSA is markedly higher in obese individuals. 2 In addition to disrupting sleep, OSA is associated with increased risk of a wide range of comorbidities, most notably cardiovascular disease and type 2 diabetes mellitus. [2] [3] [4] [5] OSA can also have a negative impact on quality of life. 6 Effective treatments for OSA should prevent the underlying upper airway obstruction, improve sleep quality, reduce the risk of comorbidities developing, and improve quality of life.
Continuous positive airway pressure (CPAP) is the mainstay of treatment for OSA and is effective in many patients. 2, 7 Unfortunately, adherence to CPAP is poor, limiting the effectiveness of this treatment approach in many instances. 8 An increasingly popular alternate treatment for OSA is the use of a mandibular advancement device (MAD). 9 MADs are less expensive and less intrusive than CPAP devices, and they can prevent or minimize upper airway collapse by protruding the mandible forward. 10 A recent review highlighted the effectiveness of MADs for the treatment of OSA, including improvements in cardiovascular health and quality of life. 9 MADs can be custom-made or made of titratable thermoplastic. The lower-cost thermoplastic option may be attractive to many patients with OSA; however, evidence suggests that adherence is significantly lower with titratable thermoplastic MADs compared with custom-made devices. 11, 12 Nevertheless, titratable thermoplastic MADs are clearly an effective treatment option in some patients with OSA. [13] [14] [15] Determining which patients may be more likely to respond to treatment with titratable thermoplastic MADs and to adhere to treatment would be of obvious clinical relevance.
The aim of this study was to compare variables, in particular cephalometric variables, between patients with OSA who were successfully treated and those not successfully treated with a specific titratable thermoplastic MAD, the SomnoGuard SP Soft (Tomed GmbH, Köln, Germany).
Patients and methods
Study design and patients. This was an experimental descriptive study carried out at the outpatient clinic of the Department of Otolaryngology at China Medical University Hospital (Taichung, Taiwan) between January 2009 and July 2011.
Patients who received a polysomnographic (PSG)-confirmed diagnosis of OSA, defined as an apnea-hypopnea index (AHI) >5, and declined first-line treatment with CPAP were eligible for inclusion in the study. Exclusion criteria were current or previous treatment for OSA (surgery or CPAP), anatomic abnormalities of the oral cavity (i.e., cleft palate), dental structure defects (i.e., periodontal disease, missing teeth, and previous root canal treatment), a recent weight change of >10%, or lack of a cohabitant partner to report snoring.
This study was approved by the Institutional Review Board of China Medical University, and all patients provided written informed consent prior to participation. Mandibular advancement device. All patients were treated with the SomnoGuard SP Soft MAD. This MAD is a two-part, incrementally adjustable device made from a soft, transparent copolymer. Two connectors laterally combine the upper and lower jaw trays and facilitate the incremental advancement of the lower jaw by up to 10 mm (figure 1).
Patients were provided with illustrated instructions and an Internet link to an instructional video describing how to fit the MAD at home. The fitting process involved placing the tray in boiling water to soften the thermoplastic material. In addition, the authors provided home visit consultations. Senior nurses visited every patient after MAD treatment began to ensure that the patient was wearing the device correctly.
Patients were instructed to wear the MAD nightly. They returned after 3 months for a follow-up visit to assess treatment efficacy.
Assessments. Patients were evaluated at baseline and after 3 months of wearing the MAD nightly. The following evaluations were performed: polysomnography to assess AHI, mean oxygen saturation (SaO 2 ), and sleep efficiency; Epworth Sleepiness Scale questionnaire to assess daytime sleepiness; and acoustic pharyngometry 16 to assess pharyngeal volume.
PSG data were recorded using a computerized PSG system (Alice 4, Healthdyne Technologies; Atlanta, Ga.). This system consists of a standardized setup of two-channel electroencephalograms (C4/A1, C3/A2), bilateral electro-oculograms (EOGs), submental electromyograms (EMGs), bilateral leg EMGs, and electrocardiograms (ECGs).
Oxyhemoglobin saturation was monitored using a finger-probe oximetry device. The oximeter sampling rate was 1 Hz. For pulse rates <112 beats/min (BPM), the average calculation was based on a 4-beat exponential average for SpO. For pulse rates ≥112 BPM, the averaging was doubled, and for rates >225 BPM, it was redoubled.
Airflow was measured via oronasal pressure, and respiratory effort was measured by inductance plethysmography. The data were digitized for computer analysis using MATLAB (MathWorks, Inc.; Natick, Mass.) software. Artifacts were handled by eliminating all oxygen saturation changes between consecutive sampling intervals of >4%/seconds, and any oxygen saturation <50% using an automated algorithm.
The data were scored by a certified (Taiwan Sleep Medicine Society) sleep technician (per the criteria of Rechtschaffen and Kales) and reviewed by an experienced physician. Arousals were defined as episodes lasting 3 seconds or longer characterized by a return of alpha activity with a discernible increase in EMG activity. Apnea was classified as a cessation of oronasal airflow for a minimum of 10 seconds. Hypopnea was defined as a reduction of oronasal airflow to ≤50% of the value occurring during a preceding period of normal breathing, for at least 10 seconds, and associated with oxyhemoglobin desaturation of 4% and/or EEG arousal.
Patients underwent radiographic study to assess the following cephalometric variables at baseline and while wearing the MAD: body (mm, the length of the mandible body); ramus (mm, the length of the mandible ramus); posterior airway space (linear distance between a point on the base of the tongue and another point on the posterior pharyngeal wall); mandible angle (degree, the angle formed by the mandibular ramus and the mandibular body); mandible plane (MP); hyoidale (H; the most superior, anterior point on the body of the hyoid bone); distance between H and MP (the plan from constructed gonion to menton); anterior nasal spine (Ans); posterior nasal spine (Pns); Ans-Pns (mm, the distance between Ans and Pns); soft palate (P); distance between Pns and P (Pns-P, the length of the soft palate); sella (S); nasion (N); subspinal (A, the deepest point of the subspinal concavity); supramentale (B, the deepest point of the supramentale concavity); the angle formed between the points S-N-A (SNA); the angle formed between the points S-N-B (SNB); condylion (Cd); gnathion (Gn); the distance between Gn and Cd (Cd-Gn); the angle between the Cd-to-Gn plane and the Ans-to-Pns plane (Cd-Gn/Ans-Pns).
Variables that would not be affected with MAD use appear in figure 2 , and those that would be affected with MAD use appear in figure 3 .
Patients provided self-assessments of sleep quality at baseline and after MAD treatment using a visual analogue scale (VAS). Sleep quality was rated from 0 (worst quality) to 10 (best quality). Patients also rated their feeling of waking up refreshed, in which a score of 0 indicated not refreshed at all and a score of 10 indicated fully refreshed. Cohabitant partners of patients completed a VAS for the patient's snoring intensity at baseline and after MAD treatment. Snoring was rated from 0 (no snoring) to 10 (loud and continuous snoring).
At the end of the 3-month treatment period, patients completed a questionnaire about their experiences with the MAD. The questionnaire included 6 questions: 4 yes/no questions asking patients if they experienced excessive salivation, device loosening or displacement, tooth pain/discomfort, or temporomandibular joint pain/discomfort; 1 yes/no question asking patients if they used the MAD 5 or more nights per week; and 1 open-answer question asking why patients discontinued using the device (if they had done so). Patients who did not return for follow-up were excluded from the analysis.
Treatment success and adherence were assessed for each patient. MAD treatment success was defined as a ≥50% reduction from baseline in AHI or an AHI <10 in patients with a baseline AHI ≥10. 17, 18 Adherence was defined as wearing the device for 5 or more nights per week.
Statistical analysis. Non-normal distributed data are presented as median with interquartile range and were compared by the nonparametric Mann-Whitney test. Other continuous data are presented as mean ± standard deviation and were compared by independent samples t test, whereas categorical data are presented as count and percentage and were compared by Fisher's exact test. Comparisons were made between the data obtained at baseline and data obtained during MAD use, and between patients in whom treatment was and was not successful. The changes from baseline to 3 months were tested with the paired t test and Wilcoxon signed rank tests for normally and non-normally distributed data, respectively. All statistical assessments were two-sided and evaluated at the 0.05 level of significance. Statistical analyses were performed using the Statistical Package for the Social Sciences (v. 15.0) software.
Results
Demographic and clinical characteristics. During the study period, a total of 756 patients were diagnosed with OSA. Of these patients, 696 did not meet the eligibility criteria; hence, 60 patients were included in the study. Patient characteristics are summarized in table 1. Most patients included were men (86.7%). Treatment was successful in 66.7% of patients. Sixty percent of patients were adherent to treatment. There were no differences in patient characteristics, including success rate and adherence, between patients with a baseline AHI between 5 and 30, and patients with a baseline AHI >30.
Sleep parameters and cephalometry. Significant improvements from baseline were noted for most sleep parameters (table 2) . Specifically, for polysomnographic parameters, AHI was significantly decreased, whereas mean SaO 2 and sleep efficiency were significantly increased (all p < 0.05). For the VAS measures, scores were significantly decreased for snoring, sleep quality, and awaking refreshed (all p < 0.001). Pharyngeal volume was also significantly increased (p < 0.001). For cephalometric measures, PAS and the Cd-Gn/ Ans-Pns angle were significantly increased, whereas MP-H was significantly decreased (all p < 0.05).
TREATMENT SUCCESS WITH TITRATABLE THERMOPLASTIC MANDIBULAR ADVANCEMENT DEVICES FOR OBSTRUCTIVE SLEEP APNEA: A COMPARISON OF PATIENT CHARACTERISTICS
Comparisons between patients for whom treatment was and was not successful. Comparisons between patients for whom treatment was and was not successful are summarized in tables 3 to 7. All patients in whom treatment failed were male and 32 of the 40 (80.0%) in the group that succeeded were male (p = 0.043).
The neck circumferences in the group in which treatment failed were significantly higher than those in the group in which treatment succeeded (39.3 vs. 37.5 cm, p = 0.014).
The group in which treatment failed had significantly higher baseline AHI values than the group in which treatment succeeded (26.6 vs. 18.0, p = 0.016), and had a smaller AHI reduction than the group with successful treatment, since treatment success was defined as an AHI reduction of ≥50% or AHI <10 after the MAD was placed.
There were no other significant differences in polysomnography, cephalometry, or VAS measures between patients for whom treatment was and was not successful, regardless of baseline values or the change rates after the MAD was placed. Reasons for not regularly using the MAD. The self-reported reasons for not using the MAD in the 24 nonadherent users were discomfort in 14 (58.3%), not wanting to use the MAD in 3 (12.5%), loosening or displacement during use in 3 (12.5%), and no particular reason in 4 (16.7%). Discomfort included teeth, jaw, or joint pain and/or soreness and general discomfort.
Discussion
To our knowledge, this is the first study to compare the characteristics between treatment success and failure of patients with OSA treated with titratable thermoplastic MADs. Aside from AHI, there were few significant differences in the characteristics between patients who experienced successful treatment vs. those in whom treatment failed. The percentage of adherence was approximately the same (60.0%) in the two groups of patients.
We found that treatment was successful (as determined by assessment of AHI) in 66.7% of all patients who used the titratable thermoplastic MAD for 3 months. This rate of treatment success is similar to the rates (60 to 75%) reported with more expensive, custom-made MADs, 13, 19, 20 and is higher than rates (41 to 50%) reported with the same titratable thermoplastic MAD. 11, 14, 15, 21 Previous studies showed that custom-made MADs are more effective than titratable thermoplastic MADs.
In a crossover study, Vanderveken and colleagues found that the treatment success rate was approximately double with customized MADs compared with titratable thermoplastic MADs. 12 Friedman et al also found that custom-made MADs were significantly more effective than titratable thermoplastic MADs. 11 Nevertheless, our results establish an excellent alternative for patients who cannot afford the expense of a custom-made MAD. With the growing knowledge of physiologic characteristics of OSA and the improving materials science and engineering, continued research into which patients may benefit from use of these much lower-cost devices is warranted. 22 Notably, we found few differences in polysomnographic, cephalometric, and VAS measures between patients in whom treatment was successful and those in whom treatment failed. This finding is important given the significant overall improvements in polysomnographic and VAS measures observed, and suggests that patients in whom treatment fails, as defined by assessment of AHI, may still benefit from use of titratable thermoplastic MADs. These patients exhibit improvements in sleep-related parameters. We did not find any differences between the treatment success and failure groups in any other cephalometric variables. Notably, there were no differences in MP-H length, which has been previously associated with treatment success. [23] [24] [25] The lack of any difference in the MP-H length between patients in whom treatment failed and those who had successful treatment in our study may reflect the different clinical characteristics of our patient population compared with those in previous studies.
This study has some limitations that warrant mentioning. First, the study was of limited duration, and the sample size was relatively small. Second, the study design is associated with several inherent limitations/biases (i.e., some nonadherent patients were not analyzed because they were lost to follow-up and thus the adherence rate might have been overestimated).
A larger-scale, randomized, controlled trial would be beneficial to further investigate factors that may affect treatment success and adherence with titratable thermoplastic MADs. A study involving a much larger number of patients would also allow for more sophisticated statistical analyses and to identify factors associated with treatment success. Third, the results presented herein only apply to the specific MAD device used: the Som- noGuard SP. Similar studies with other MAD devices would be of interest. In summary, we have found that use of a titratable thermoplastic MAD effectively reduced the symptoms of OSA in approximately 70% of patients over a 3-month period. Approximately 60% of patients were adherent to treatment. Notably, symptoms were improved in patients considered to have failed treatment by AHI measures. With further study, these measures may prove useful in deciding on treatment strategies and indeed whether particular patients should be treated with this device. Furthermore, customized titratable thermoplastic MADs may be a viable option for patients who experience improvement with noncustomized MADs, but have problems tolerating the device.
